<DOC>
	<DOCNO>NCT01588912</DOCNO>
	<brief_summary>Oral antiviral drug give patient HBeAg-positive chronic hepatitis B include Lamivudine , Clevudine , Adefovir , Telbivudine , Entecavir Tenofovir . 2009 American Association Study Liver Disease ( AASLD ) Treatment Guidelines 2009 European association Study Liver ( EASL ) Treatment Guidelines recommend administration Entecavir Tenofovir high potency low resistance . Lamivudine low antiviral potency high incidence mutation long-term administration compare Entecavir Tenofovir . Clevudine cause elevated creatinine kinase ( CK ) , side effect include myositis/myopathy much mutation long-term administration . Globe study demonstrate Telbivudine excellent antiviral potency Lamivudine , also comparable high Entecavir Tenofovir . Nevertheless , choice treatment drug limit due mutation rate 25 % 2 year . However , analysis Globe study result show 2-year treatment progress good patient show virologic response 24 week initiation treatment high antiviral potency low mutation rate observe Telbivudine roadmap strategy ( event virologic response show 24 week , telbivudine monotherapy maintain event virologic response show , tenofovir add-on therapy do ) recently implement announced 2011 Asian Pacific Association Study Liver ( APASL ) apply . However , study single arm study , restrict comparison Entecavir Tenofovir monotherapy group . Therefore , study intend compare anti-viral effect mutation rate Entecavir 0.5mg monotherapy group Telbivudine roadmap strategy group patient HBeAg-positive chronic hepatitis B randomize study .</brief_summary>
	<brief_title>Efficacy Telbivudine With Without add-on Tenofovir According Roadmap Strategy Compare With Entecavir</brief_title>
	<detailed_description>104 treatment-naïve patient HBeAg-positive chronic hepatitis B fulfill inclusion criterion randomize 1:1 ratio receive either Telbivudine 600mg monotherapy Entecavir monotherapy stratification randomization accord presence cirrhosis . For Telbivudine group , Telbivudine monotherapy Tenofovir combine therapy do accord virologic response 24 week primary study complete Week 48 treatment response analyze . The treatment extend Week 96 secondary analysis perform .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Male female , least 18 year age Documented CHB define HBsAg HBeAg positive least 6 month prior HBsAg positive screen visit HBeAg positive AntiHBe negative screen visit Serum HBV DNA 20,000~200,000,000 IU/mL determine Realtime PCR screen visit Serum ALT 80~400 IU/mL screen visit Patient willing able comply study drug regimen study requirement Patient willing able provide write informed consent participate study Patient receive interferon , pegylated interferon , nucleoside nucleotide drug time Patient coinfected HCV , HDV , HIV Patient Child Pugh B C ( Child Pugh score ≥ 7 ) Patient history clinical signs/symptoms hepatic decompensation ascites , esophageal variceal bleeding , hepatic encephalopathy Patient follow laboratory value screen visit : Hemoglobin &lt; 10 g/dL Absolute neutrophil count ( ANC ) &lt; 1,500/mm3 Platelet count &lt; 70,000/mm3 Patient history clinical laboratory evidence chronic renal insufficiency define estimate serum creatinine clearance &lt; 50 mL/min use MDRD formula screen visit Patient pregnant breastfeeding Patient currently abuse illegal drug alcohol sufficient Patient organ transplantation History acute chronic medical condition opinion investigator would make patient unsuitable inclusion study Patient one additional know primary secondary cause liver disease , CHB , include steatohepatitis autoimmune hepatitis Patient , AFP &gt; 50ng/mL screen visit , image finding suggestive HCC Liver CT Liver MRI Patient hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>chronic hepatitis B</keyword>
	<keyword>HBeAg positive</keyword>
	<keyword>telbivudine</keyword>
	<keyword>tenofovir</keyword>
	<keyword>entecavir</keyword>
	<keyword>roadmap</keyword>
</DOC>